Press Brief

Hu5F9 plus rituximab to overcome resistance in refractory lymphoma

Mark Roschewski

ASCEND-ing results: acalabrutinib is well-tolerated and highly effective in R/R CLL

Venetoclax with bortezomib/dexamethasone: phase 3 BELLINI results in R/R myeloma

EHA 2019 program: insights from the Chair of the Scientific Program Committee

Maria-Victoria Mateos

New double targeting approach for beta-thalassemia

Imetelstat provides durable transfusion independence in lower risk MDS group

Pregnancy outcomes in CML patients

Ekaterina Chelysheva

Fixed-duration therapy with venetoclax-obinutuzumab in frontline CLL

Kirsten Fischer

Genomic residual disease in AML prior to allo-SCT: fate or early intervention opportunity?

Christopher Hourigan

Data from the Phase 3 CASSIOPEIA trial: D-VTd vs. VTd

Philippe Moreau

HOPE for sickle cell: promising data for voxelotor

PAUSE: perioperative management of AF patients receiving direct oral anticoagulants

Long-term follow-up after SCRI-CAR19v1 in R/R ALL patients who proceeded to transplant

Corinne Summers

Updated pivotal ELIANA study results for CAR T-cell product tisagenlecleucel in ALL

Genetic targeting in sickle cell disease

Specific BCL2 mutation confers resistance to venetoclax in progressive CLL

1
2
3
4
5
Next